Medical and surgical management of advanced Parkinson's disease
- PMID: 29570862
- DOI: 10.1002/mds.27340
Medical and surgical management of advanced Parkinson's disease
Abstract
Advanced Parkinson's disease is characterized by the presence of motor fluctuations, various degree of dyskinesia, and disability with functional impact on activities of daily living and independence. Therapeutic management aims to extend levodopa benefit while minimizing motor complications and includes, in selected cases, the implementation of drug infusion and surgical techniques. In milder forms of motor complications, these can often be controlled with manipulation of levodopa dose and the introduction of supplemental therapies such as catechol-O-methyl transferase inhibitors, monoamine oxidase B inhibitors, and dopamine agonists including apomorphine. Clinical experience and evidence from published studies indicate that when these agents cannot satisfactorily control motor complications, patients should be assessed and considered for device-aided therapies. This review article summarizes some of the newer available therapeutic opportunities such as use of enzyme inhibitors like opicapone and safinamide, adenosine A2A receptor antagonists, apomorphine and levodopa/carbidopa intestinal gel infusion, deep brain stimulation including the role of closed-loop and adaptive stimulation, and MRI-guided focused ultrasound. © 2018 International Parkinson and Movement Disorder Society.
Keywords: MR focused ultrasound; apomorphine; deep brain stimulation; dyskinesia; inhaled levodopa; levodopa infusion gel; motor complications; opicapone; safinamide; wearing-off.
© 2018 International Parkinson and Movement Disorder Society.
Similar articles
-
Current and novel infusion therapies for patients with Parkinson's disease.J Neural Transm (Vienna). 2023 Nov;130(11):1349-1358. doi: 10.1007/s00702-023-02693-8. Epub 2023 Sep 6. J Neural Transm (Vienna). 2023. PMID: 37672049 Free PMC article. Review.
-
Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.Drugs. 2019 Apr;79(6):593-608. doi: 10.1007/s40265-019-01098-w. Drugs. 2019. PMID: 30905034 Review.
-
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.Mov Disord. 2018 Oct;33(10):1528-1539. doi: 10.1002/mds.27475. Epub 2018 Sep 27. Mov Disord. 2018. PMID: 30264443 Review.
-
[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].Fortschr Neurol Psychiatr. 2018 Sep;86(S 01):S5-S9. doi: 10.1055/a-0646-4164. Epub 2018 Aug 14. Fortschr Neurol Psychiatr. 2018. PMID: 30107620 Review. German.
-
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.J Neural Transm (Vienna). 2018 Aug;125(8):1131-1135. doi: 10.1007/s00702-018-1906-0. Epub 2018 Jul 13. J Neural Transm (Vienna). 2018. PMID: 30006821 Review.
Cited by
-
Advanced therapies in Parkinson's disease: an individualized approach to their indication.J Neural Transm (Vienna). 2024 Apr 13. doi: 10.1007/s00702-024-02773-3. Online ahead of print. J Neural Transm (Vienna). 2024. PMID: 38613674 Review.
-
Efficacy of acupuncture (Jin's three-needle) on motor symptoms and anxiety in patients with Parkinson's disease: protocol for a multicentre, randomised, assessor-blinded clinical trial.BMJ Open. 2024 Mar 28;14(3):e081312. doi: 10.1136/bmjopen-2023-081312. BMJ Open. 2024. PMID: 38548359 Free PMC article.
-
[Rho kinase inhibitor Y27632 promotes survival of human induced pluripotent stem cells during differentiation into functional midbrain dopaminergic progenitor cells in vitro].Nan Fang Yi Ke Da Xue Xue Bao. 2024 Feb 20;44(2):236-243. doi: 10.12122/j.issn.1673-4254.2024.02.05. Nan Fang Yi Ke Da Xue Xue Bao. 2024. PMID: 38501408 Free PMC article. Chinese.
-
Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson's disease.Mol Biol Rep. 2024 Feb 24;51(1):347. doi: 10.1007/s11033-024-09294-y. Mol Biol Rep. 2024. PMID: 38400887 Review.
-
Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms.Neurol Sci. 2024 Jul;45(7):2979-2995. doi: 10.1007/s10072-023-07278-7. Epub 2024 Feb 23. Neurol Sci. 2024. PMID: 38388896 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical